Recent investigations have converged on the overlap of glucagon-like peptide-1|GIP|GCGR agonist therapies and dopaminergic neurotransmission. While GIP stimulators are commonly employed for managing type 2 diabetes, their unexpected consequences on reinforcement circuits, specifically influenced